Stage III Non-Small Cell Lung Cancer Clinical Trial
Official title:
Phase II Study on Dose Escalated, Accelerated Hypofractionated Intensity Modulated Radiotherapy for Stage III Non-Small Cell Lung Cancer With Concurrent Chemotherapy
Locally advanced non-small cell lung cancer can be treated successfully with chemotherapy
and radiation. However, the cure rate is low.
This study is carried out to find out whether giving radiotherapy at a higher dose over
fewer treatment sessions with intensity modulated radiotherapy (IMRT) can improve the
treatment outcome.
This study aims to recruit 43 patients from National University Hospital and Tan Tock Seng
Hospital over a period of about 2 years.
n/a
Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Active, not recruiting |
NCT05488626 -
Daily Adaptive Radiation Therapy: An Individualized Approach for Stage III Lung Cancer
|
N/A | |
| Recruiting |
NCT02076282 -
MRI Optimization Study in Stage III NSCLC
|
N/A | |
| Terminated |
NCT01577212 -
Individualized Dose Prescription in Advanced Stage Lung Cancer Patients Using Modern (Chemo)Radiotherapy
|
Phase 2 | |
| Withdrawn |
NCT01336543 -
Consolidation Chemotherapy/Concurrent Chemo-radiotherapy for Inoperable Stage III Non-small Cell Lung Cancer (NSCLC)
|
Phase 2 | |
| Completed |
NCT01102231 -
Chemoradiotherapy in Stage III Non-small Cell Lung Cancer (NSCLC)
|
Phase 2 | |
| Completed |
NCT00019006 -
Vaccine Therapy in Treating Patients With Colon, Pancreatic, or Lung Cancer
|
Phase 1 | |
| Recruiting |
NCT06082492 -
The Beneficial Value of PET/CT in the Follow-up of Stage III Non-small Cell Lung Cancer Patients
|
N/A | |
| Active, not recruiting |
NCT03049618 -
Recombinant EphB4-HSA Fusion Protein and Pembrolizumab, MK-3475
|
Phase 2 | |
| Recruiting |
NCT03077854 -
Image-Guided Functional Lung Avoidance Thoracic Radiotherapy for Lung Cancer: A Single-Blind Randomized Trial
|
N/A | |
| Recruiting |
NCT05157542 -
Neoadjuvant LDRT Combined With Durvalumab in Potentially Resectable Stage III NSCLC
|
Phase 1 | |
| Recruiting |
NCT05361174 -
A Study to Investigate the Efficacy and Safety of an Infusion of IOV-4001 in Adult Participants With Unresectable or Metastatic Melanoma or Stage III or IV Non-small-cell Lung Cancer
|
Phase 1/Phase 2 | |
| Active, not recruiting |
NCT03048500 -
Nivolumab and Metformin Hydrochloride in Treating Patients With Stage III-IV Non-small Cell Lung Cancer That Cannot Be Removed by Surgery
|
Phase 2 | |
| Not yet recruiting |
NCT05891080 -
Neoadjuvant Therapy With Toripalimab and JS004 Combined With Platinum-based Doublet Chemotherapy for Resectable or Potentially Resectable Stage III Non-small Cell Lung Cancer: A Randomised Controlled, Open-label, Phase 2 Trial
|
Phase 2 | |
| Active, not recruiting |
NCT01948141 -
Nintedanib in Treating Patients With Advanced Non-Small Cell Lung Cancer Who Have Failed Up to Two Previous Chemotherapy Regimens
|
Phase 2 | |
| Completed |
NCT01282437 -
Prophylactic Cranial Irradiation (PCI) vs Observation in Stage III NSCLC
|
Phase 3 | |
| Recruiting |
NCT05631574 -
Study of Covalent Menin Inhibitor BMF-219 in Adult Patients With KRAS Driven Non-Small Cell Lung Cancer, Pancreatic Cancer, and Colorectal Cancer
|
Phase 1 | |
| Recruiting |
NCT05157503 -
Treatment of Patients With Stage III Non-small Cell Lung Cancer in Russia"
|
||
| Recruiting |
NCT05468242 -
Study of Tislelizumab for Locally Advanced Non-Small Cell Lung Cancer Following Neoadjuvant Chemotherapy Plus Tislelizumab ± Bevacizumab and Definitive Concurrent Chemoradiation Therapy
|
Phase 2 | |
| Active, not recruiting |
NCT06102057 -
PACCELIO - FDG-PET Based Small Volume Accelerated Immuno Chemoradiotherapy in Locally Advanced NSCLC
|
Phase 2 | |
| Recruiting |
NCT04984148 -
Construction of CT Radiomics Model for Predicting the Efficacy of Immunotherapy in Patients With Stage III NSCLC
|